Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Idorsia Ltd    IDIA   CH0363463438

IDORSIA LTD (IDIA)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
12/08/2017 12/11/2017 12/12/2017 12/13/2017 Date
21.1(c) 20.9(c) 20.7(c) 21.25(c) 21.4 Last
242 471 251 674 328 161 215 457 215 457 Volume
+0.96% -0.95% -0.96% +2.66% +0.71% Change
More quotes
Financials ( CHF)
Sales 2017 88,1 M
EBIT 2017 -69,8 M
Net income 2017 -231 M
Finance 2017 493 M
Yield 2017 -
Sales 2018 58,7 M
EBIT 2018 -331 M
Net income 2018 -340 M
Finance 2018 313 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 23,1x
EV / Sales2018 37,8x
Capitalization 2 531 M
More Financials
Company
Idorsia Ltd. is a biopharmaceutical company engages in the development of medicines.It specializes in the discovery and development of small molecules used for therapeutic products.It focuses on diseases such as hypertension, systemic lupus erythematosus, chronic insomnia, Aneurysmal subarachnoid... 
More about the company
Latest news on IDORSIA LTD
12/05 IDORSIA : announces collaboration with Janssen Biotech on aprocitentan (ACT-1325..
12/05 ACTELION : J&J opts in on Idorsias candidate for $230m
12/05 IDORSIA : J&J snaps up Idorsias resistant hypertension candidate, paying $230M
12/05 JOHNSON & JOHNSON : J&J opts in for Idorsia's hypertension candidate
12/04 IDORSIA : to get $230 million from J&J in latest hypertension deal
12/04 IDORSIA : announces collaboration with Janssen Biotech on aprocitentan (ACT-1325..
12/04 IDORSIA : announces collaboration with Janssen Biotech on aprocitentan (ACT-1325..
10/24 IDORSIA : announces financial results as of 30 September 2017
10/16 IDORSIA : Invitation to Idorsia's nine-month results 2017 webcast and conference..
08/03 IDORSIA : announces half year results for 2017 - successful start of new biophar..
More news
Sector news : Bio Therapeutic Drugs
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Bio Therapeutic Drugs
Chart IDORSIA LTD
Duration : Period :
Idorsia Ltd Technical Analysis Chart | IDIA | CH0363463438 | 4-Traders
Technical analysis trends IDORSIA LTD
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 16,1  CHF
Spread / Average Target -24%
EPS Revisions
Managers
NameTitle
Jean-Paul Clozel Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
André C. Muller Chief Financial Officer & Executive Vice President
Martine Clozel Chief Scientific Officer & Executive VP
Robert J. Bertolini Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IDORSIA LTD0.00%2 570
GILEAD SCIENCES3.64%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS94.94%35 831
GENMAB0.85%11 452
BLUEBIRD BIO INC177.39%9 249